Exelixis General and Administrative Expenses 2011-2026 | EXEL

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Exelixis

2026	2025	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
519 M	492 M	543 M	460 M	402 M	228 M	228 M	206 M	159 M	57.3 M	57.3 M	50.8 M	51 M	31.8 M	33.1 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
543 M	31.8 M	235 M

Quarterly General and Administrative Expenses Exelixis

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
124 M	135 M	137 M	-	112 M	132 M	114 M	-	138 M	142 M	131 M	-	115 M	123 M	103 M	-	102 M	98.5 M	102 M	-	88.2 M	59.8 M	62.9 M	-	51.3 M	58.8 M	60.1 M	-	48.1 M	51.9 M	54 M	-	38.1 M	40.7 M	34.3 M	-	32.5 M	35.8 M	34.9 M	-	17.8 M	12.8 M	9.53 M	-	9.91 M	16.5 M	14.7 M	-	13.6 M	13.2 M	10.5 M	-	7.34 M	6.76 M	7.9 M	-	8.17 M	8.78 M	9.16 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
142 M	6.76 M	60.6 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Amgen AMGN	7.05 B	$ 350.62	0.81 %	$ 189 B	USA
Heron Therapeutics HRTX	54.6 M	$ 0.8	2.35 %	$ 133 M	USA
Altimmune ALT	28.1 M	$ 3.46	3.44 %	$ 305 M	USA
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Ascendis Pharma A/S ASND	160 M	$ 219.42	-1.11 %	$ 5 B	Danmark
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
Incyte Corporation INCY	1.38 B	$ 90.74	-0.04 %	$ 17.7 B	USA
AgeX Therapeutics AGE	9.33 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
Inovio Pharmaceuticals INO	47.6 M	$ 1.62	2.22 %	$ 35.9 M	USA
Aileron Therapeutics ALRN	13.9 M	-	10.36 %	$ 9.8 M	USA
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Avenue Therapeutics ATXI	4.64 M	-	-52.27 %	$ 4.45 M	USA
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Cullinan Management CGEM	54.2 M	$ 12.92	1.41 %	$ 778 M	USA
Inventiva S.A. IVA	11.2 M	$ 6.13	6.06 %	$ 138 M	France
Atreca BCEL	31.5 M	-	-11.76 %	$ 5.79 M	USA
BioDelivery Sciences International BDSI	106 M	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	2.08 B	-	0.49 %	$ 251 B	Cayman-islands
KalVista Pharmaceuticals KALV	116 M	$ 16.76	-1.41 %	$ 832 M	Britain
Calithera Biosciences CALA	20.9 M	-	-10.95 %	$ 876 K	USA
Cara Therapeutics CARA	27.8 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	78.9 M	-	-	$ 3.74 B	USA
Bellerophon Therapeutics BLPH	6.02 M	-	-74.18 %	$ 955 K	USA
Kamada Ltd. KMDA	12.6 M	$ 8.23	-0.24 %	$ 260 M	Israel
Checkpoint Therapeutics CKPT	20.1 M	-	-	$ 169 M	USA
Karyopharm Therapeutics KPTI	115 M	$ 7.06	-7.47 %	$ 860 K	USA
Clovis Oncology CLVS	128 M	-	-7.23 %	$ 13 M	USA
Keros Therapeutics KROS	46.8 M	$ 11.27	2.83 %	$ 419 M	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Denali Therapeutics DNLI	105 M	$ 21.23	5.26 %	$ 3.49 B	USA
Longeveron LGVN	12 M	$ 0.95	-3.52 %	$ 16.7 B	USA
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Arbutus Biopharma Corporation ABUS	22.5 M	$ 4.3	1.3 %	$ 714 M	Canada
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
AIkido Pharma AIKI	29.7 M	-	1.93 %	$ 17.4 M	USA